{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:53:23Z","timestamp":1774925603714,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFF1205104"],"award-info":[{"award-number":["2023YFF1205104"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC2506402"],"award-info":[{"award-number":["2023YFC2506402"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011408","name":"State Key Laboratory of Medicinal Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204197"],"award-info":[{"award-number":["82204197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118496","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:08:44Z","timestamp":1765843724000},"page":"118496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synthesis and optimization of LHQ766: A highly selective FGFR2 inhibitor with improved pharmacokinetics"],"prefix":"10.1016","volume":"304","author":[{"given":"Huiqiong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuju","family":"Xun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinglian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8762-6089","authenticated-orcid":false,"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2025.118496_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118496_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118496_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118496_bib4","first-page":"3893","article-title":"Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118496_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"issue":"7923","key":"10.1016\/j.ejmech.2025.118496_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118496_bib7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118496_bib8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118496_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.ejmech.2025.118496_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","article-title":"Futibatinib: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118496_bib11","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118496_bib12","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118496_bib13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1021\/acs.jmedchem.1c01163","article-title":"From fragment to lead: de novo design and development toward a selective FGFR2 inhibitor","volume":"65","author":"Turner","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118496_bib14","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118496_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118496_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116473","article-title":"Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor","volume":"272","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118496_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117339","article-title":"Discovery of BW710 as a potent, selective and orally bioavailable fibroblast growth factor receptor 2 (FGFR2) inhibitor","volume":"287","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118496_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116780","article-title":"Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer","volume":"277","author":"Feng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118496_bib19","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118496_bib20","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1021\/ja00371a056","article-title":"Mechanism of cytochrome P-450 inhibition by cyclopropylamines","volume":"104","author":"Macdonald","year":"1982","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118496_bib21","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1021\/ja054938+","article-title":"Cytochrome P450-catalyzed oxidation of N-benzyl-N-cyclopropylamine generates both cyclopropanone hydrate and 3-hydroxypropionaldehyde via hydrogen abstraction, not single electron transfer","volume":"128","author":"Cerny","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118496_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:17:34Z","timestamp":1773919054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"alternative-id":["S0223523425012619"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118496","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and optimization of LHQ766: A highly selective FGFR2 inhibitor with improved pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118496"}}